[
    {
        "trialName": "A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)",
        "nctNumber": "NCT05325866",
        "statusVerifiedDate": "2024-07",
        "overallStatus": "RECRUITING",
        "startDate": "2022-09-23",
        "primaryCompletionDate": "2025-10-05",
        "completionDate": "2027-07-27",
        "studyFirstSubmitDate": "2022-04-06",
        "lastUpdateSubmitDate": "2024-07-31",
        "startDateType": "ACTUAL",
        "durationDays": 1768,
        "daysUntilEnd": 1084
    },
    {
        "trialName": "A Phase 1 Study of SGN-B7H4V in Advanced Solid Tumors",
        "nctNumber": "NCT05194072",
        "statusVerifiedDate": "2024-07",
        "overallStatus": "RECRUITING",
        "startDate": "2022-01-12",
        "primaryCompletionDate": "2025-06-30",
        "completionDate": "2027-01-31",
        "studyFirstSubmitDate": "2022-01-03",
        "lastUpdateSubmitDate": "2024-07-29",
        "startDateType": "ACTUAL",
        "durationDays": 1845,
        "daysUntilEnd": 907
    },
    {
        "trialName": "A Phase II Trial of Carboplatin +/- Tocilizumab as Initial Therapy for Metastatic Triple Negative and ER-low Breast Cancers",
        "nctNumber": "NCT05846789",
        "statusVerifiedDate": "2024-06",
        "overallStatus": "RECRUITING",
        "startDate": "2024-07",
        "primaryCompletionDate": "2026-12",
        "completionDate": "2026-12",
        "studyFirstSubmitDate": "2023-04-27",
        "lastUpdateSubmitDate": "2024-06-06",
        "startDateType": "ESTIMATED",
        "durationDays": 883,
        "daysUntilEnd": 846
    },
    {
        "trialName": "A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors",
        "nctNumber": "NCT03821935",
        "statusVerifiedDate": "2024-04",
        "overallStatus": "RECRUITING",
        "startDate": "2019-02-21",
        "primaryCompletionDate": "2027-06-23",
        "completionDate": "2027-06-23",
        "studyFirstSubmitDate": "2019-01-28",
        "lastUpdateSubmitDate": "2024-04-29",
        "startDateType": "ACTUAL",
        "durationDays": 3044,
        "daysUntilEnd": 1050
    },
    {
        "trialName": "A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)",
        "nctNumber": "NCT04849364",
        "statusVerifiedDate": "2023-08",
        "overallStatus": "RECRUITING",
        "startDate": "2021-08-24",
        "primaryCompletionDate": "2029-01-31",
        "completionDate": "2034-01-31",
        "studyFirstSubmitDate": "2021-04-13",
        "lastUpdateSubmitDate": "2023-11-09",
        "startDateType": "ACTUAL",
        "durationDays": 4543,
        "daysUntilEnd": 3464
    },
    {
        "trialName": "An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
        "nctNumber": "NCT04225117",
        "statusVerifiedDate": "2024-07",
        "overallStatus": "RECRUITING",
        "startDate": "2020-03-09",
        "primaryCompletionDate": "2026-09-30",
        "completionDate": "2026-09-30",
        "studyFirstSubmitDate": "2020-01-09",
        "lastUpdateSubmitDate": "2024-07-19",
        "startDateType": "ACTUAL",
        "durationDays": 2396,
        "daysUntilEnd": 784
    },
    {
        "trialName": "OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy With Checkpoint Inhibitor Therapy",
        "nctNumber": "NCT05812807",
        "statusVerifiedDate": "2024-08",
        "overallStatus": "RECRUITING",
        "startDate": "2023-05-10",
        "primaryCompletionDate": "2033-05-31",
        "completionDate": "2033-05-31",
        "studyFirstSubmitDate": "2023-03-23",
        "lastUpdateSubmitDate": "2024-08-01",
        "startDateType": "ACTUAL",
        "durationDays": 3674,
        "daysUntilEnd": 3219
    },
    {
        "trialName": "A Phase I/II Study of VLS-1488 (an Oral KIF18A Inhibitor) in Subjects With Advanced Cancer",
        "nctNumber": "NCT05902988",
        "statusVerifiedDate": "2024-05",
        "overallStatus": "RECRUITING",
        "startDate": "2023-10-18",
        "primaryCompletionDate": "2025-12",
        "completionDate": "2026-06",
        "studyFirstSubmitDate": "2023-05-31",
        "lastUpdateSubmitDate": "2024-05-15",
        "startDateType": "ACTUAL",
        "durationDays": 957,
        "daysUntilEnd": 663
    },
    {
        "trialName": "A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy",
        "nctNumber": "NCT05633654",
        "statusVerifiedDate": "2024-06",
        "overallStatus": "RECRUITING",
        "startDate": "2022-12-12",
        "primaryCompletionDate": "2027-06",
        "completionDate": "2031-08",
        "studyFirstSubmitDate": "2022-11-21",
        "lastUpdateSubmitDate": "2024-06-24",
        "startDateType": "ACTUAL",
        "durationDays": 3154,
        "daysUntilEnd": 2550
    }
]